Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Change in Receivables (2019 - 2025)

Voyager Therapeutics (VYGR) has disclosed Change in Receivables for 4 consecutive years, with -$1.4 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 90.14% to -$1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $257000.0 through Dec 2025, up 100.33% year-over-year, with the annual reading at $257000.0 for FY2025, 100.33% up from the prior year.
  • Change in Receivables hit -$1.4 million in Q4 2025 for Voyager Therapeutics, down from $1.5 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $25.0 million in Q1 2023 to a low of -$79.3 million in Q1 2024.
  • Historically, Change in Receivables has averaged -$5.9 million across 3 years, with a median of $119000.0 in 2025.
  • Biggest five-year swings in Change in Receivables: crashed 417.25% in 2024 and later surged 100.15% in 2025.
  • Year by year, Change in Receivables stood at $25.0 million in 2023, then crashed by 157.8% to -$14.4 million in 2024, then soared by 90.14% to -$1.4 million in 2025.
  • Business Quant data shows Change in Receivables for VYGR at -$1.4 million in Q4 2025, $1.5 million in Q3 2025, and $51000.0 in Q2 2025.